FRM
APLS

Fox Run Management’s Apellis Pharmaceuticals APLS Stock Holding History

Fox Run Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-27,223
Closed -$616K – 890
2025
Q3 		$616K Buy
27,223
+13,256
+95% +$309K 0.1% 403
2025
Q2 		$242K Sell
13,967
-1,745
-11% -$32.3K 0.04% 703
2025
Q1 		$344K Buy
+15,712
New +$434K 0.05% 629
2024
Q3 		– Sell
-22,102
Closed -$848K – 786
2024
Q2 		$848K Buy
+22,102
New +$1M 0.16% 231
2024
Q1 		– Sell
-5,235
Closed -$313K – 739
2023
Q4 		$313K Sell
5,235
-1,198
-19% -$60.8K 0.08% 481
2023
Q3 		$245K Buy
6,433
+4,136
+180% +$182K 0.07% 509
2023
Q2 		$209K Buy
+2,297
New +$198K 0.06% 570
2022
Q4 		– Sell
-10,819
Closed -$739K – 603
2022
Q3 		$739K Buy
+10,819
New +$640K 0.29% 67

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Fox Run Management's APLS Position: Q4 2025 in Review

Fox Run Management sold out of Apellis Pharmaceuticals (APLS) in Q4 2025, closing a stake of 27,223 shares — an estimated $616K sold.

Fox Run Management first reported a position in APLS in Q3 2022 and held it in 8 quarters. The position peaked at $848K in Q2 2024. 279 funds tracked by Wall St. Rank hold APLS as of Q4 2025.

  • Fox Run Management reported no remaining Apellis Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Fox Run Management sold 27,223 Apellis Pharmaceuticals shares in Q4 2025, an estimated $616K.
  • Fox Run Management first reported a position in Apellis Pharmaceuticals in Q3 2022 and held it in 8 quarters.
  • Fox Run Management's Apellis Pharmaceuticals position peaked at $848K in Q2 2024.
  • 279 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2025.

Based on Fox Run Management's 13F filing for Q4 2025, filed 11 Feb 2026.